Skip to main content

Peer Review reports

From: Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Original Submission
28 Apr 2021 Submitted Original manuscript
8 Jun 2021 Reviewed Reviewer Report - Bérenger KABORE
14 Jun 2021 Reviewed Reviewer Report - Hesamaddin Shirzad-Aski
30 Jun 2021 Author responded Author comments - Wendy Holman
Resubmission - Version 2
30 Jun 2021 Submitted Manuscript version 2
11 Jul 2021 Reviewed Reviewer Report - Hesamaddin Shirzad-Aski
12 Jul 2021 Reviewed Reviewer Report - Bérenger KABORE
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
9 Aug 2021 Editorially accepted
23 Aug 2021 Article published 10.1186/s13063-021-05538-5

You can find further information about peer review here.

Back to article page